Search

Your search keyword '"Sanchez Schmidt, J. M."' showing total 6 results
Start Over Author "Sanchez Schmidt, J. M."
6 results on '"Sanchez Schmidt, J. M."'

1. [Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study

Author

Minano Medrano, R, Lopez Estebaranz, J L, Sanmartin-Jimenez, O, Garces, J R, Rodriguez-Prieto, M A, Vilarrasa-Rull, E, de Eusebio-Murillo, E, Escutia-Munoz, B, Florez-Menendez, A, Artola-Igarza, J L, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, J M, Allende-Markixana, I, Alonso-Pacheco, M L, Garcia-Bracamonte, B, de la Cueva-Dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Ruiz-Salas, V, Sanchez-Sambucety, P, Botella-Estrada, R, Gonzalez-Sixto, B, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, M A, and Garcia-Doval, I

Subjects
Carcinoma epidermoide cutáneo, Incidence, Carcinoma basocelular, General Medicine, Segunda neoplasia, Risk factors, Second cancer, Squamous cell carcinoma, Basal cell carcinoma, Cirugía micrográfica de Mohs, Incidencia, Mohs micrographic surgery, Factores de riesgo
Abstract

OBJECTIVE: Patients with nonmelanoma skin cancer (NMSC)-ie, basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)-have an increased risk of developing a second skin cancer. The aim of this study was to describe the frequency, incidence per 1000 person-years, and predictors of a second skin cancer in a cohort of patients with NMSC treated with Mohs micrographic surgery (MMS). MATERIAL AND METHODS: Prospective study of a national cohort of patients with NMSC who underwent MMS at 22 Spanish hospitals between July 2013 and February 2020; case data were recorded in the REGESMOHS registry. The study variables included demographic characteristics, frequency and incidence per 1000 person-years of second skin cancers diagnosed during the study period, and risk factors identified using mixed-effects logistic regression. RESULTS: We analyzed data for 4768 patients who underwent MMS; 4397 (92%) had BCC and 371 (8%) had SCC. Mean follow-up was 2.4 years. Overall, 1201 patients (25%) developed a second skin cancer during follow-up; 1013 of the tumors were BCCs (21%), 154 were SCCs (3%), and 20 were melanomas (0.4%). The incidence was 107 per 1000 person-years (95% CI, 101-113) for any cancer, 90 per 1000 person-years (95% CI, 85-96) for BCC, 14 (95% CI, 12-16) per 1000 person-years for SCC, and 2 (95% CI, 1-3) per 1000 person-years for melanoma. More men than women developed a subsequent skin cancer (738 [61%] vs 463 [39%]). The main risk factors were a history of multiple tumors before diagnosis (relative risk [RR], 4.6; 95% CI, 2.9-7.1), immunosuppression (RR, 2.1; 95% CI, 1.4-3.1), and male sex (RR, 1.6; 95% CI, 1.4-1.9). CONCLUSION: Patients have an increased risk of developing a second tumor after MMS treatment of NMSC. Risk factors are a history of multiple tumors at diagnosis, immunosuppression, and male sex.

Published
2022
Full Text
View/download PDF

2. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.

Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first-and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.

Published
2017

3. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.

Abstract

The term sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).

Published
2017

4. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Alexander Kreuter, Annamari Ranki, L.A. Frasin, Armando Gabrielli, Anna Skrok, J.M. Sanchez Schmidt, Maurizio Cutolo, Margitta Worm, Cord Sunderkötter, K. Kofoed, Elisabeth Aberer, Pia Moinzadeh, Nora Wutte, Julien Seneschal, Jaana Panelius, Dorota Krasowska, Michael Sticherling, T. Krieg, Antonio Cozzio, Jean-David Bouaziz, Christopher P. Denton, Antoine Petit, Martine Bagot, Franco Rongioletti, Lidia Rudnicka, Pietro Quaglino, Ulrike Just, I. Foeldvari, A. Jalili, Sarolta Kárpáti, Malgorzata Olszewska, Alain Taieb, Adrian Tanew, Robert Knobler, Philipp Wolf, Luc Mouthon, Nicolas Hunzelmann, Vanessa Smith, A. Braae Olesen, C. Orteu, Andrea Parodi, G. Bali, Camille Francès, Veli-Matti Kähäri, Knobler, R, Moinzadeh, P, Hunzelmann, N, Kreuter, A, Cozzio, A, Mouthon, L, Cutolo, M, Rongioletti, Franco, Denton, C. P, Rudnicka, L, Frasin, L. A, Smith, V, Gabrielli, A, Aberer, E, Bagot, M, Bali, G, Bouaziz, J, Braae Olesen, A, Foeldvari, I, Frances, C, Jalili, A, Just, U, Kähäri, V, Kárpáti, S, Kofoed, K, Krasowska, D, Olszewska, M, Orteu, C, Panelius, J, Parodi, A, Petit, A, Quaglino, P, Ranki, A, Sanchez Schmidt, J. M, Seneschal, J, Skrok, A, Sticherling, M, Sunderkötter, C, Taieb, A, Tanew, A, Wolf, P, Worm, M, Wutte, N. J, and Krieg, T.

Subjects
medicine.medical_specialty, RAYNAUDS-PHENOMENON, Placebo-controlled study, INTENSE PULSED-LIGHT, Physical examination, Dermatology, PLACEBO-CONTROLLED TRIAL, Scleroderma, 030207 dermatology & venereal diseases, 03 medical and health sciences, DOUBLE-BLIND, 0302 clinical medicine, Infectious Diseases, medicine, ta319, Localized Scleroderma, 030203 arthritis & rheumatology, DOSE UVA1 PHOTOTHERAPY, medicine.diagnostic_test, DIGITAL ULCERS, business.industry, BROAD-BAND UVA, STEM-CELL TRANSPLANTATION, Guideline, ta3121, medicine.disease, Connective tissue disease, 3. Good health, CONNECTIVE-TISSUE DISEASE, Differential diagnosis, ULTRAVIOLET A1 PHOTOTHERAPY, business, Morphea
Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first-and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.

Published
2017
Full Text
View/download PDF

5. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

Author

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, and Krieg T

Subjects
Diagnosis, Differential, Humans, Nephrogenic Fibrosing Dermopathy pathology, Scleredema Adultorum pathology, Scleromyxedema pathology, Nephrogenic Fibrosing Dermopathy diagnosis, Nephrogenic Fibrosing Dermopathy therapy, Scleredema Adultorum diagnosis, Scleredema Adultorum therapy, Scleromyxedema diagnosis, Scleromyxedema therapy
Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy)., (© 2017 European Academy of Dermatology and Venereology.)

Published
2017
Full Text
View/download PDF

6. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Author

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, and Krieg T

Subjects
Humans, Diagnosis, Differential, Europe, Physical Examination, Prognosis, Scleroderma, Localized diagnosis, Scleroderma, Localized pathology, Scleroderma, Localized therapy, Scleroderma, Systemic diagnosis, Scleroderma, Systemic pathology, Scleroderma, Systemic therapy, Undifferentiated Connective Tissue Diseases diagnosis, Undifferentiated Connective Tissue Diseases pathology, Undifferentiated Connective Tissue Diseases therapy
Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum., (© 2017 European Academy of Dermatology and Venereology.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results